Sanofi K.K has announced that Allegra dry syrup 5% has launched in Japan.
The new formulation of fexofenadine HCI was the result of a co-development partnership between Sanofi K.K and Aptalis Pharmaceutical Technologies.
Allegra dry syrup 5% is indicated for treatment of allergic rhinitis, urticaria, and pruritus associated with dermal disorders such as eczema/dermatitis, pruritus cutaneous, and atopic dermatitis.
By using Microcaps taste masking technology, Aptalis successfully masked the taste of the bitter API, delivering a formulation with a pleasant taste in a dosage form that features white granules that can be sprinkled on easy-to-swallow foods to improve administration.
The formulation can be used with or without the need for water or mixed into a liquid suspension.
Microcaps is a proprietary technology that provides complete and uniform encapsulation of drug particles in a polymeric membrane of adjustable thickness.
It can be applied to crystals, drug-layered beads, or granules, and can be combined with pore-former technology to ensure rapid release in the stomach, while maintaining effective taste masking.
Allegra Dry Syrup 5% is an appropriate alternative to the tablet formulation for pediatric patients and adult patients who have difficulty swallowing.
Adults should receive 60mg of fexofenadine hydrochloride orally twice a day, suspended at time of use. Dosage may be changed as appropriate based on symptoms.
Normally, 60mg of fexofenadine hydrochloride for children over the age of 12 can be administered, or 30mg of fexofenadine hydrochloride for children between the age of seven and 12 should be given orally twice a day, suspended at time of use. Dosage may be changed as appropriate based on symptoms.
The normal dosage for children between the age of two and seven is 30mg of fexofenadine hydrochloride, or 15mg of fexofenadine hydrochloride for children from six months of age and less than two years old should be given orally twice a day, suspended at the time of use.